› Forums › General Melanoma Community › Melanoma in Stomach-Help
- This topic has 3 replies, 1 voice, and was last updated 11 years, 8 months ago by
Bubbles.
- Post
-
- September 6, 2014 at 12:58 am
I am new to this and was wondering if anyone has had melanoma in the stomach/intestines. My husband was recently diagnosed and has had 4 treatments of ipi (Yervoy). The tumor did not shrink, in fact it may have gotten larger. The tumor is NOT Braf and we do not know what the mutation is. Now he is receiving the new Merck drug pembrolizmab or MK-2437 ?? Not sure if that is the right number combo. I can find very little information and wondered if anyone was currently receiving this pembro and was also not Braf positive and what results they are having. Also he seems to run a temperature all the time so he is pretty uncomfortable. I know that is because if is in the gut but wondering how other folks are coping with this. Any information would be helpful. Thanks so much and God Bless.
- Replies
-
-
- September 6, 2014 at 1:31 pm
So sorry for all that you are dealing with, Jean and Mike. Actually, a dear one of mine has been dealing with intestinal melanoma and is not BRAF postive either. He is responding very well to Pembro!!! (Now called Keytruda since its FDA approval this week.) I could not lay my hands on some data that shows folks responding just as well with/without BRAF positive status to Pembro…but here is one addressing that with the BMS anti-PD1 product, Nivolumab….and they act pretty much identically in all the data so far, though no head-to-head comparison has been done.
Survival, response duration, and activity by BRAF mutation status of nivolumab (anti-PD1, BMS-936588) and ipilimumab concurrent therapy in advanced melanoma
Abstract LBA9003
Sznol, Kluger, Kirkwood, Wolchok, et al53 melanoma patients were enrolled from 2009-2012 and were given ipi and nivo concurrently, then followed by nivo alone (with a variety of dosing patterns). Patients with and without BRAF had similar response.
There is a good deal more information about anti-PD1 and melanoma generally on my blog if you are interested. Just use the bubble in the top left corner to search for what you are interested in.
Hope this helps and I wish you and your husband my best. I think you have reason for a great deal of hope.
Yours, Celeste
-
- September 6, 2014 at 1:31 pm
So sorry for all that you are dealing with, Jean and Mike. Actually, a dear one of mine has been dealing with intestinal melanoma and is not BRAF postive either. He is responding very well to Pembro!!! (Now called Keytruda since its FDA approval this week.) I could not lay my hands on some data that shows folks responding just as well with/without BRAF positive status to Pembro…but here is one addressing that with the BMS anti-PD1 product, Nivolumab….and they act pretty much identically in all the data so far, though no head-to-head comparison has been done.
Survival, response duration, and activity by BRAF mutation status of nivolumab (anti-PD1, BMS-936588) and ipilimumab concurrent therapy in advanced melanoma
Abstract LBA9003
Sznol, Kluger, Kirkwood, Wolchok, et al53 melanoma patients were enrolled from 2009-2012 and were given ipi and nivo concurrently, then followed by nivo alone (with a variety of dosing patterns). Patients with and without BRAF had similar response.
There is a good deal more information about anti-PD1 and melanoma generally on my blog if you are interested. Just use the bubble in the top left corner to search for what you are interested in.
Hope this helps and I wish you and your husband my best. I think you have reason for a great deal of hope.
Yours, Celeste
-
- September 6, 2014 at 1:31 pm
So sorry for all that you are dealing with, Jean and Mike. Actually, a dear one of mine has been dealing with intestinal melanoma and is not BRAF postive either. He is responding very well to Pembro!!! (Now called Keytruda since its FDA approval this week.) I could not lay my hands on some data that shows folks responding just as well with/without BRAF positive status to Pembro…but here is one addressing that with the BMS anti-PD1 product, Nivolumab….and they act pretty much identically in all the data so far, though no head-to-head comparison has been done.
Survival, response duration, and activity by BRAF mutation status of nivolumab (anti-PD1, BMS-936588) and ipilimumab concurrent therapy in advanced melanoma
Abstract LBA9003
Sznol, Kluger, Kirkwood, Wolchok, et al53 melanoma patients were enrolled from 2009-2012 and were given ipi and nivo concurrently, then followed by nivo alone (with a variety of dosing patterns). Patients with and without BRAF had similar response.
There is a good deal more information about anti-PD1 and melanoma generally on my blog if you are interested. Just use the bubble in the top left corner to search for what you are interested in.
Hope this helps and I wish you and your husband my best. I think you have reason for a great deal of hope.
Yours, Celeste
-
- You must be logged in to reply to this topic.